Selinexor治疗复发或难治性弥漫大B细胞淋巴瘤(SADAL):一项单臂、跨国、多中心、开放标签的2期试验
SADAL是一项在19个国家59个中心开展的单臂、开放标签2b期研究,评估口服Selinexor 60 mg每周两次在127例复发或难治性弥漫大B细胞淋巴瘤患者中的疗效与安全性。总缓解率为28%(36/127;95%CI 20.7-37.0),其中完全缓解15例(12%)、部分缓解21例(17%);最常见3-4级不良事件为血小板减少(n=58)、中性粒细胞减少(n=31)和贫血(n=28),无治疗相关死亡。作者认为Selinexor可考虑作为该人群新的口服非细胞毒性治疗选择。
要点
- Selinexor 60 mg每周两次口服在复发或难治性DLBCL中总缓解率28%(36/127;95%CI 20.7-37.0)。
- 完全缓解15例(12%)、部分缓解21例(17%),最常见3-4级不良事件为血小板减少(n=58)。
- 作者认为Selinexor可考虑作为该人群新的口服非细胞毒性治疗选择。
核心结论
- 单药口服Selinexor在既往接受至少两线化学免疫治疗的复发或难治性DLBCL患者中诱导持久缓解,不良事件可控。
- 作者认为Selinexor可考虑作为该人群新的口服非细胞毒性治疗选择。
研究设计与样本
- SADAL是一项在19个国家59个中心开展的多中心、跨国、开放标签2b期研究。
- 研究纳入年龄≥18岁、病理确诊DLBCL、ECOG体能状态≤2、既往接受2-5线治疗且自体干细胞移植后进展或不适合移植的患者。
- 患者接受Selinexor 60 mg口服,每周第1天和第3天给药,直至疾病进展或不可耐受毒性。
- 研究最初设计评估60 mg和100 mg每周两次剂量,100 mg剂量于2017年3月29日在方案版本7.0中因60 mg观察到更优治疗窗而停止。
- 主要终点为总缓解率,在方案版本6.0下接受60 mg Selinexor或方案版本7.0及以上入组并至少接受一剂Selinexor的所有患者中评估疗效和安全性。
主要发现
- 2015年10月21日至2019年11月2日期间,267例患者被随机分配,其中175例分配至60 mg组、92例分配至已停止的100 mg组。
- 60 mg组中48例因在方案版本6.0之前入组而被排除,剩余127例接受Selinexor 60 mg并纳入主要终点和安全性分析。
- 总缓解率为28%(36/127;95%CI 20.7-37.0),其中完全缓解15例(12%)、部分缓解21例(17%)。
- 最常见3-4级不良事件为血小板减少(n=58)、中性粒细胞减少(n=31)、贫血(n=28)、疲乏(n=14)、低钠血症(n=10)和恶心(n=8)。
- 最常见严重不良事件为发热(n=9)、肺炎(n=6)和脓毒症(n=6);无判定为与Selinexor治疗相关的死亡。
关键数值与推荐
- 总缓解率28%(36/127;95%CI 20.7-37.0)。
- 完全缓解15例(12%),部分缓解21例(17%)。
- 3-4级血小板减少n=58,中性粒细胞减少n=31,贫血n=28,疲乏n=14,低钠血症n=10,恶心n=8。
- 严重不良事件:发热n=9,肺炎n=6,脓毒症n=6。
临床怎么用
- 作者认为Selinexor可考虑作为复发或难治性DLBCL患者新的口服非细胞毒性治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single-agent selinexor, an oral selective inhibitor of nuclear export, in patients with relapsed or refractory DLBCL who had no therapeutic options of potential clinical benefit. METHODS: SADAL was a multicentre, multinational, open-label, phase 2b study done in 59 sites in 19 countries. Patients aged 18 years or older with pathologically confirmed diffuse large B-cell lymphoma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received two to five lines of previous therapies, and progressed after or were not candidates for autologous stem-cell transplantation were enrolled. Germinal centre B-cell or non-germinal centre B-cell tumour subtype and double or triple expressor status were determined by immunohistochemistry and double or triple hit status was determined by cytogenetics. Patients received 60 mg selinexor orally on days 1 and 3 weekly until disease progression or unacceptable toxicity. The study was initially designed to evaluate both 60 mg and 100 mg twice-weekly doses of selinexor; however, the 100 mg dose was discontinued in the protocol (version 7.0) on March 29, 2017, when an improved therapeutic window was observed at 60 mg. Primary outcome was overall response rate. The primary outcome and safety were assessed in all patients who received 60 mg selinexor under protocol version 6.0, or enrolled under protocol versions 7.0 or higher and received at least one dose of selinexor. This trial is registered at ClinicalTrials.gov, NCT02227251 (active but not enrolling). FINDINGS: Between Oct 21, 2015, and Nov 2, 2019, 267 patients were randomly assigned, with 175 allocated to the 60 mg group and 92 to the discontinued 100 mg group. 48 patients assigned to the 60 mg group were excluded due to enrolment before version 6.0 of the protocol; the remaining 127 patients received selinexor 60 mg and were included in analyses of primary outcome and safety. The overall response rate was 28% (36/127; 95% CI 20·7-37·0); 15 (12%) achieved a complete response and 21 (17%) a partial response. The most common grade 3-4 adverse events were thrombocytopenia (n=58), neutropenia (n=31), anaemia (n=28), fatigue (n=14), hyponatraemia (n=10), and nausea (n=8). The most common serious adverse events were pyrexia (n=9), pneumonia (n=6), and sepsis (n=6). There were no deaths judged as related to treatment with selinexor. INTERPRETATION: Single-drug oral selinexor induced durable responses and had a manageable adverse events profile in patients with relapsed or refractory DLBCL who received at least two lines of previous chemoimmunotherapy. Selinexor could be considered a new oral, non-cytotoxic treatment option in this setting. FUNDING: Karyopharm Therapeutics Inc.
引用
- Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020. PMID: 32589977. doi:10.1016/S2352-3026(20)30120-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。